The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 20 April 2026•Updated 20 April 2026•

1 min read

Genflow Biosciences Partners with Acuitas Therapeutics for Gene Therapy Development

Key Facts

1Genflow Biosciences announced a strategic technology collaboration with Acuitas Therapeutics to utilize their lipid nanoparticle (LNP) delivery platform.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to specify the operational workflow, confirming Genflow is providing the mRNA payload for formulation ahead of preclinical trials, and adding specific stock tickers and exchange listings.

Genflow Biosciences has announced a strategic technology collaboration with Acuitas Therapeutics to utilize its world-class lipid nanoparticle (LNP) delivery platform. Under the agreement, Genflow will provide its proprietary SIRT6 mRNA payload to Acuitas for formulation, with the resulting materials returned to Genflow for preclinical evaluation. This fully funded, non-dilutive partnership is designed to advance Genflow's SIRT6 platform for age-related disease therapies. By leveraging Acuitas's proven delivery systems, Genflow aims to accelerate its clinical development pipeline. The company, which trades on the London Stock Exchange (LSE:GENF) and the US OTC markets (OTCQB:GENFF), continues to focus on integrating industry-leading technology. Analysts view this as a bullish development, as it secures high-tier technical support while avoiding shareholder dilution.